Shares of Dianthus Therapeutics Inc (DNTH) are soaring 6.06% in pre-market trading on Friday, despite reporting mixed second-quarter results. The biotechnology company's stock movement comes on the heels of its earnings release, which showed a slightly larger loss than expected but highlighted strong analyst confidence in the company's future.

Dianthus reported a quarterly adjusted loss of $0.88 per share, marginally missing the consensus estimate of $0.87 per share. Revenue for the quarter fell sharply by 89.6% to $193,000, well below analyst expectations of $864,330. Despite these disappointing figures, investors appear to be focusing on the company's long-term potential rather than its current financial performance.

The stock's surge can be attributed to overwhelmingly positive analyst sentiment. The current average analyst rating for Dianthus Therapeutics is a "strong buy," with 13 analysts recommending either "strong buy" or "buy," and no "hold" or "sell" ratings. Moreover, Wall Street's median 12-month price target for the company stands at $51.00, representing a substantial 62.5% upside from its last closing price of $19.15. This optimistic outlook, coupled with the absence of recent negative earnings revisions, seems to be outweighing the impact of the missed quarterly results, driving the stock's pre-market rally.